NewsBenzingaロズウェル・パークとGenerate Biomedicines、自己由来IL-18装甲CAR-T細胞療法の治験薬GB-5267を評価するヒト初回投与の臨床試験で最初の患者への投与を発表 ロズウェル・パークとGenerate Biomedicines、自己由来IL-18装甲CAR-T細胞療法の治験薬GB-5267を評価するヒト初回投与の臨床試験で最初の患者への投与を発表 Benzinga 2026.10.01 11:14 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Kodiak AI, Lowers Price Target to $7 Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says